Breaking News, Collaborations & Alliances

Amarantus, Generex In Pre-Diabetes Research Pact

Companies collaborate on second candidate for MANF-based therapeutic for the treatment of the beta cell destruction at the root of diabetes.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amarantus BioSciences and Generex Biotechnology, Inc. have selected a second program under their joint research collaboration for the development of a MANF-based therapeutic for the treatment of the beta cell destruction at the root of diabetes. The first collaboration is for the development of a MANF-based diagnostic test to identify a sub-population at risk of developing Type 1 or Type 2 diabetes. “Taken together with the MANF-based early diabetes detection diagnostic, the potential the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters